Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened. Guests: Dr. Grant, who has been working on H.I.V. treatment and prevention for over 30 years, and Donald G. McNeil Jr., a science and health reporter for The New York Times. For more information on today’s episode, visit nytimes.com/thedaily.
- Gilead Sciences, the maker of Truvada, the only drug approved to prevent H.I.V. infection, will donate enough of the drug to supply 200,000 patients, but critics questioned the company’s motives.
- The high cost of drugs remains a major obstacle to ending the AIDS epidemic.
- Here’s more information about PrEP from the Centers for Disease Control and Prevention website.